Conference on Retroviruses and Opportunistic Infections (CROI)
Conference on Retroviruses and Opportunistic Infections (CROI)
March 13, 2018
3 min watch
Save

VIDEO: HCV-positive to HCV-negative transplant recipients remain uninfected after 1 year

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

BOSTON — In this video, Christine M. Durand, MD, a transplant infectious diseases specialist at Johns Hopkins University School of Medicine, discusses the potential of using organs from donors with HIV or hepatitis C virus infection to address an “organ shortage crisis” in the United States.

Durand says HIV-positive to HIV-positive organ transplants can now be performed under the HIV Organ Policy Equity (HOPE) Act of 2013. A team at Johns Hopkins Medicine was the first to successfully perform such a transplant in the U.S. in March 2016. Since then, more than 45 HIV-positive to HIV-positive transplants have been performed in the country, Durand says.

In addition, surgeons at Johns Hopkins have also performed organ transplants involving HCV-positive donors and HCV-negative recipients who are given direct-acting antivirals for both pre- and post-exposure prophylaxis. In a small study of 10 HCV-positive to HCV-negative transplants, Durand reported that all recipients were free of HCV 1-year post-surgery.

“We hope that this represents another potential way to expand the organ donor pool for individuals in need of live-saving transplants,” she says. “I hope that everyone will consider registering as an organ donor and remember that having a health condition such as HIV or HCV does not prevent you from being an organ donor.”

Reference:

Durand C, et al. Abstract 166. Presented at: Conference on Retroviruses and Opportunistic Infections; March 4-7, 2018; Boston.

Disclosure: Durand reports a relationship with Gilead Sciences, being a consultant for Merck, and receiving research grants from GlaxoSmithKline and Merck.